News

As many Americans face difficult financial decisions thanks to inflation, a new study verifies what many have feared for years: drug prices are significantly higher than in the past. According to a new report published in the Journal of the...

Bluebird bio has persuaded an expert committee that the benefits of its gene therapy possibility, eli-cel, exceed the risks, at least in certain patients, after encountering major safety concerns from FDA reviewers. The FDA invited its Cellular, Tissue, and...

Alnylam has outlined their strategy for delivering siRNA to the central nervous system and other organs outside of the liver. The RNA specialist detailed how the coupling of its drug candidates permitted therapeutic suppression of target genes across the...

Merck & Co. was not at all a prominent oncology player before the advent of Keytruda. The New Jersey drugmaker wants to consolidate its supremacy now that it has the world's best-selling cancer medication. Jannie Oosthuizen, Merck's head of global...

Roche is exploring new products to refill its blood cancer armoury after Rituxan's patent expiration. Swiss pharma is launching a novel bispecific lymphoma medicine with a first-in-class clearance that will compete with strong CAR-T therapies. Lunsumio, or mosunetuzumab, has acquired...

It was a small study, with only 18 rectal cancer sufferers taking the same medicine. However, the outcomes were astounding. Every single patient's cancer vanished, undetected by physical examination, endoscopy, positron emission tomography, PET scans, or MRI scans. Dr. Luis A. Diaz...

The findings of a phase 1 trial examining a medication mixture targeting multiple mutant variants of cancer's 'death star' protein have been released by the Institute of Cancer Research (ICR) in London and The Royal Marsden NHS Foundation Trust. In...